Onsdag 26 November | 17:53:10 Europe / Stockholm

Prenumeration

Kalender

Est. tid*
2026-02-28 08:00 Bokslutskommuniké 2025
2025-10-21 - Kvartalsrapport 2025-Q3
2025-07-24 - Kvartalsrapport 2025-Q2
2025-06-30 - X-dag ordinarie utdelning PTRK 0.00 SEK
2025-06-27 - Årsstämma
2025-05-13 - Kvartalsrapport 2025-Q1
2025-02-28 - Bokslutskommuniké 2024
2024-11-12 - Kvartalsrapport 2024-Q3
2024-08-13 - Kvartalsrapport 2024-Q2
2024-05-14 - Kvartalsrapport 2024-Q1
2024-05-06 - X-dag ordinarie utdelning PTRK 0.00 SEK
2024-05-03 - Årsstämma
2024-02-29 - Bokslutskommuniké 2023
2023-11-14 - Kvartalsrapport 2023-Q3
2023-08-15 - Kvartalsrapport 2023-Q2
2023-05-04 - X-dag ordinarie utdelning PTRK 0.00 SEK
2023-05-03 - Årsstämma
2023-05-02 - Kvartalsrapport 2023-Q1
2023-02-28 - Bokslutskommuniké 2022
2022-11-07 - Kvartalsrapport 2022-Q3
2022-08-25 - Kvartalsrapport 2022-Q2
2022-05-26 - Kvartalsrapport 2022-Q1
2022-05-04 - X-dag ordinarie utdelning PTRK 0.00 SEK
2022-05-03 - Årsstämma
2022-02-24 - Bokslutskommuniké 2021
2021-10-20 - Kvartalsrapport 2021-Q3
2021-07-28 - Kvartalsrapport 2021-Q2

Beskrivning

LandStorbritannien
ListaFirst North Stockholm
SektorInformationsteknik
IndustriProgramvara
Physitrack är verksamt inom hälsovårdssektorn och specialiserat inom sjukgymnastik. Produktportföljen inkluderar digitala vårderbjudanden till företag via SaaS-lösningar. Utöver huvudverksamheten erbjuds även personlig service och tillhörande kringtjänster. Verksamheten drivs globalt med störst närvaro inom Europa och Nordamerika. Physitrack grundades år 2012 och har sitt huvudkontor i London.

Intresserad av bolagets nyckeltal?

Analysera bolaget i Börsdata!

Vem äger bolaget?

All ägardata du vill ha finns i Holdings!

2025-11-24 16:15:00

London, 24 November 2025 – Physitrack PLC ("Physitrack") announces the continued restructuring of its Wellness division as part of the Group's strategy to focus on high-margin, recurring-revenue software in 2026.

As part of this restructuring, the Group will exit human-intensive, lower-margin care operations in Wellness and focus on its core SaaS platforms in Physitrack and Champion Health. This includes the divestment of Fysiotest / Champion Health Nordics and the closure of all remaining clinics in Champion Health Plus. 

This strategy is a continuation of the work initiated in 2024 and 2025 to focus the Group, improve profitability and reinforce Physitrack as a SaaS-led business. The divestments and closures do not affect Physitrack’s core SaaS platforms, where demand and growth opportunities remain strong heading into 2026.

Summary highlights (pro forma YTD to 30 September 2025)

Had the divestment and clinic closures taken effect from 1 January 2025:

  • Revenue impact: –€1.0m
  • Adjusted EBITDA impact: +€0.2m
  • Adjusted EBITDA margin: 38%, compared with the reported 32%
  • Cash impact: +€0.1m
  • Recurring revenue mix: would have been 95% of Group revenue (vs 86% reported)

These changes strengthen the Group’s financial profile, improve revenue visibility and support a more scalable, software-driven growth trajectory into 2026 and beyond.

Intended divestment of Fysiotest AB / Champion Health Nordics
Physitrack has signed Heads of Terms with existing management for a potential divestment of Fysiotest Europa AB / Champion Health Nordics through a management buy-out. Completion, subject to contract, is targeted for the end of December 2025.

  • Expected consideration: €1
  • Estimated disposal costs (adjusting items): approx. €0.1m
  • Goodwill and intangible assets to be derecognised: €1.6m (carrying value at 30 September 2025)

Contracts relating to the Champion Health Swedish platform will remain with Physitrack’s Champion Health business, with Nordic sales activities now led from London. As part of the finalisation of the SPA, Physitrack expects to enter into a reseller distribution agreement with existing management to continue selling the platform in the region.
2) Champion Health Plus – closure of clinic operations
Physitrack will close the remaining Champion Health Plus clinics and retain the asset-light elements of the business, including the National Network offering and the Nexa digital triage platform.

  • Estimated closure-related costs (adjusting items): approx. €0.2–0.3m
  • Impairment of related goodwill and intangibles: €3.3m (carrying value at 30 September 2025)

The retained activities align fully with Physitrack’s SaaS and digital health strategy, supporting scalable and margin-accretive growth.

Management commentary
Henrik Molin, CEO and Co-founder of Physitrack, commented:

"These actions complete the Wellness pivot to pure-play SaaS we started in 2024. By exiting labour-intensive care operations and focusing fully on our SaaS and digital platforms, we position Physitrack for sustainable, high-margin growth in 2026 and beyond."

Forward-looking statements
This press release contains forward-looking statements that reflect management's current expectations and assumptions about future events and financial performance. These statements are subject to risks and uncertainties that may cause actual results to differ materially, including but not limited to market conditions, customer demand, integration and execution risks, regulatory developments and the final terms and timing of the transactions described. Physitrack undertakes no obligation to update any forward-looking statements, except as required by applicable law.